Imu asx

Financial Times Close. Search the FT Search. Show more World link World.

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved. ASX shareholders. Our Board.

Imu asx

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes an off-the-shelf allogeneic cell therapy CAR T drug Azer-Cel azercabtagene zapreleucel which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia pox virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech.

Its product pipeline includes an off-the-shelf allogeneic cell therapy CAR T drug Azer-Cel azercabtagene zapreleucel which targets CD19 to attack blood cancer. Dividend Yield 0. Investment options, imu asx.

Imugene Limited. Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. About the company. IMU Stock Overview Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Earnings are forecast to grow

Key events shows relevant news articles on days with large price movements. Race Oncology Ltd. RAC Immutep Ltd. IMM 8. Pilbara Minerals Ltd. PLS 0. Sayona Mining Ltd. SYA 2.

Imu asx

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved. ASX shareholders. Our Board. Corporate governance. Media centre.

Transparent shed roofing

Drapkin also served on transaction committees for both companies. Scott Phillips just released his 5 best stocks to buy right now and you could grab the names of these stocks instantly! November 6, Bernd Struben. Chief Financial Officer Company Secretary. Days Range -. Yesterday's Close. Please check your inbox. Before joining Jounce, Ms Drapkin managed a financial consulting firm and served as interim CFO for various early-stage biotech companies, including Eleven Biotherapeutics, Inc. Public consultations. Price target decreased by 9. Corporate governance.

Financial Times Close. Search the FT Search.

Chief Executive Officer Managing Director. Analyst Coverage. Future Growth. Many thanks for your interest in Team Imugene. Apply to become a participant. Participation in share purchase plan. Any information that you receive via FT. Investor Presentations. Mr Hopper has over 20 years experience in the management and funding of biotechnology and healthcare public companies as chairman, chief executive officer and director in Australia and the United States. Our latest Newsletter. Volume 1 month. Issuer Services.